Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaneck Pharmaceutical ETF (NQ: PPH )

92.02 +0.12 (+0.13%)
Streaming Delayed Price Updated: 10:09 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,828
Open 92.41
Bid (Size) 92.01 (1)
Ask (Size) 92.04 (1)
Prev. Close 91.90
Today's Range 92.01 - 92.58
52wk Range 74.05 - 93.85
Shares Outstanding N/A
Dividend Yield 1.69%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss... 
Via Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. 
Via InvestorPlace

Performance

YTD
+11.36%
+11.36%
1 Month
-0.15%
-0.15%
3 Month
+7.10%
+7.10%
6 Month
+8.67%
+8.67%
1 Year
+13.93%
+13.93%

More News

Read More
A Look At Pharma ETFs Post Q1 Earnings
Via Talk Markets
Topics ETFs
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
Via Talk Markets
Topics ETFs
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Via InvestorPlace
Topics ETFs
Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage
Via Benzinga
Exposures Product Safety
The Top 3 ETFs to Buy in March 2024
Via InvestorPlace
Topics ETFs
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
Via Benzinga
A Look At Pharma ETFs After Q4 Earnings
Via Talk Markets
Topics ETFs
5 ETF Zones Scaling New Highs At The Start Of 2024
Via Talk Markets
Topics ETFs
Government-granted Patent Monopolies Are Not The Free Market
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
Preparing For The Next Short-Term Rally Higher
Via Talk Markets
Pharma ETFs in Focus Post Q2 Earnings
Via Talk Markets
Topics ETFs
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Via InvestorPlace
Pharma ETFs Gain Post Q1 Earnings
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Via Talk Markets
5 Sector ETFs That Beat The Market In December
Via Talk Markets
Pharma ETFs In Focus Post Q3 Earnings
Via Talk Markets
Wave of Solid Q3 Earnings Push Pharma ETFs Higher
Via Talk Markets
Pharma ETFs in Focus Post Q1 Earnings
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.